The aim of the study was to compare randomly assigned primary angioplasty and accelerated recombinant tissue plasminogen activator (rt-PA), in patients with "high-risk" inferior acute myocardial infarction (ST-segment elevation in the inferior leads and ST-segment depression in the precordial leads).The ST-segment depression in the precordial leads is a marker of severe prognosis in patients with inferior myocardial infarction. The comparative outcome of treatment with primary angioplasty or lysis with accelerated rt-PA has not been investigated.One hundred and ten patients within 6 h of symptoms were randomized to either treatment. To assess the in-hospital and 1-year outcome of both treatments the following results were compared: death or nonfatal infarction, recurrence of angina, left ventricular ejection fraction (LVEF), and the need for repeat target vessel revascularization (TVR).In patients treated with angioplasty (55) and rt-PA (55) the rate of in-hospital mortality and reinfarction was 3.6\% versus 9.1\% (p=0.4). Recurrence of angina was 1.8\% versus 20\% (p=0.002), new TVR was used in 3.6\% versus 29.1\% (p=0.0003), and the LVEF (\%) at discharge was 55.2+/-9.5 versus 48.2+/-9.9 (p=0.0001). There were no hemorrhagic strokes, no emergency coronary artery bypass graft (CABG) and identical (5.5\%) need for blood transfusions. At 1 year, the incidence of death, reinfarction or repeat TVR was 11\% in the percutaneous transluminal coronary angioplasty (PTCA) group versus 52.7\% in the rt-PA group (log-rank 22.38, p < 0.0001).Primary angioplasty is superior to accelerated rt-PA in terms of both myocardial preservation and reduction of in-hospital complications in patients with inferior myocardial infarction and precordial ST-segment depression. Primary angioplasty also yields a better long-term event-free survival.

Comparison of thrombolytic therapy and primary coronary angioplasty with liberal stenting for inferior myocardial infarction with precordial ST-segment depression: immediate and long-term results of a randomized study.

RIBICHINI, Flavio Luciano;
1998

Abstract

The aim of the study was to compare randomly assigned primary angioplasty and accelerated recombinant tissue plasminogen activator (rt-PA), in patients with "high-risk" inferior acute myocardial infarction (ST-segment elevation in the inferior leads and ST-segment depression in the precordial leads).The ST-segment depression in the precordial leads is a marker of severe prognosis in patients with inferior myocardial infarction. The comparative outcome of treatment with primary angioplasty or lysis with accelerated rt-PA has not been investigated.One hundred and ten patients within 6 h of symptoms were randomized to either treatment. To assess the in-hospital and 1-year outcome of both treatments the following results were compared: death or nonfatal infarction, recurrence of angina, left ventricular ejection fraction (LVEF), and the need for repeat target vessel revascularization (TVR).In patients treated with angioplasty (55) and rt-PA (55) the rate of in-hospital mortality and reinfarction was 3.6\% versus 9.1\% (p=0.4). Recurrence of angina was 1.8\% versus 20\% (p=0.002), new TVR was used in 3.6\% versus 29.1\% (p=0.0003), and the LVEF (\%) at discharge was 55.2+/-9.5 versus 48.2+/-9.9 (p=0.0001). There were no hemorrhagic strokes, no emergency coronary artery bypass graft (CABG) and identical (5.5\%) need for blood transfusions. At 1 year, the incidence of death, reinfarction or repeat TVR was 11\% in the percutaneous transluminal coronary angioplasty (PTCA) group versus 52.7\% in the rt-PA group (log-rank 22.38, p < 0.0001).Primary angioplasty is superior to accelerated rt-PA in terms of both myocardial preservation and reduction of in-hospital complications in patients with inferior myocardial infarction and precordial ST-segment depression. Primary angioplasty also yields a better long-term event-free survival.
Adult, Aged, Angioplasty; Balloon; Coronary, Coronary Angiography, Electrocardiography, Female, Fibrinolytic Agents; therapeutic use, Humans, Longitudinal Studies, Male, Middle Aged, Myocardial Infarction; physiopathology/radiography/therapy, Recombinant Proteins, Stents, Survival Analysis, Thrombolytic Therapy, Tissue Plasminogen Activator; therapeutic use, Treatment Outcome
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11562/470388
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 87
  • ???jsp.display-item.citation.isi??? 70
social impact